Colon Cancer Alliance for Research & Education for Lynch Syndrome - CCARE

10/08/2026

09/25/2026

Do you have or have had an early-stage dMMR/MSI-high colon or re**al cancer treated with immunotherapy and interested in sharing your journey to educate health care professionals? Patient involvement in educational activities helps humanize the data and gives patients the opportunity to voice their perspectives to improve the delivery of care. Dr. Eldasher is conveining an expert panel and will send all recording equipment to you directly and offer a $500 honorarium for participation. Recording will be done remotely and edited prior to launch. There will be no live or virtual audience during the recording. Staff will help with all aspects of the patient's participation. Contact Dr. Lobna Eldasher at [email protected] or 609-914-5647.

06/20/2026

The new National Comprehensive Cancer Network® (NCCN®) Genetic/Familial High-Risk Assessment: Colore**al, Endometrial, Esophageal, and Gastric Cancer Guidelines - Version 1.2026 were released on June 16, 2026.Stay tuned for more important updates from the NCCN Guidelines®: Genetic/Familial High-R...

03/01/2026

Raising Awareness at Fight CRC Call On Congress. Colon cancer is now the leading cause of cancer death for people under 50. If cancer runs in your family you may need your DNA checked for hereditary cancer.

01/17/2026

Exciting news from one of the Lynch syndrome vaccine trials!

The investigational cancer vaccine, NOUS-209, was found to safely stimulate the immune system to target precancerous and cancerous cells in individuals with Lynch Syndrome (LS), according to a study from researchers at The University of Texas MD Anderson Cancer Center.

11/18/2025

https://www.instagram.com/p/DQf-klCjn4m/?utm_source=ig_web_button_share_sheet&igsh=MzRlODBiNWFlZA==

11/18/2025

Sharing an important post from our friends at FORCE:

The Patent Eligibility Restoration Act (PERA) would overturn 150 years of Supreme Court precedent and allow patents on laws of nature, products of nature, and abstract ideas. In healthcare, this would:Endanger the significant progress made in...

10/11/2025

Congratulations to Dr. Asaf Maoz, MD and his team at the Dana-Farber/ Harvard Cancer Center. They are the winner of this year’s CGA-IGC / CCARE Lynch Syndrome research grant at the 30th annual CGA-IGC conference in St. Louis. His study, Leveraging Urine cfDNA for Urinary Tract Surveillance in Lynch Syndrome, will test an improved method to identify cancers of the urinary tract (the bladder and drainage tubes). While Lynch syndrome has been widely known to cause colore**al and uterus cancers, it is also linked with urinary tract cancers. This is especially true for people with the MSH2 abnormality.

08/06/2025

Our Secretary of Human Health and Services just axed funding for mRNA vaccine research. What he probably does not realize is that mRNA vaccines are being used as new treatments for many types of cancer. Especially cancers due to Lynch syndrome. Vaccines are used by themselves or in combination with immunotherapy. Immunotherapy is the latest form of cancer treatment showing tremendous improvements compared to conventional chemotherapy. It is essential that this funding is restored ASAP. Please contact your senators and representatives about this. We need to improve our health, not go back to the stone age.

https://www.senate.gov/senators/senators-contact.htm
https://www.house.gov/representatives/find-your-representative

Not sure of your congressional district or who your member is? This service will assist you by matching your ZIP code to your congressional district, with links to your member's website and contact page. Please review the frequently asked questions if you have problems using this service. Enter your...

06/06/2025

https://www.healio.com/news/hematology-oncology/20250603/exercise-described-as-novel-firstinclass-colon-cancer-therapy

CHICAGO — A structured exercise program after surgery and adjuvant chemotherapy reduced the risk for cancer recurrence and death for certain patients with colon cancer, according to study results presented at ASCO Annual Meeting. Patients with stage III or high-risk stage II colon cancer who p...